Reach Us +44-1647-403003
Clinical Studies on Hormonal Status in Breast Cancer and its Impact on Quality of Life (QOL) | OMICS International | Abstract
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Clinical Studies on Hormonal Status in Breast Cancer and its Impact on Quality of Life (QOL)

Kaiser Jamil1,2*, Kalyan Kumar1, S. Hajira Fatima1,2, Syed Rabbani1,2, Ravi Kumar3 and Ramesh Perimi4

1School of Biotechnology- MGNIRSA, Street no-17, GaganMahal Road, Domalguda, Hyderabad-500029, A.P. India

2Genetics Department, Bhagwan Mahavir Medical Research Centre, 10-1-1, Mahavir Marg, Hyderabad-500004, AP, India

3Medical Oncologist, 11-3-936, Mallapally Clinic, Hyderabad- 500001, AP, India

4Surgical Oncologist, Mahavir Hospital and Research Centre, 10-1-1, Mahavir Marg, Hyderabad- 500004, AP, India

*Corresponding Author:
Dr. Kaiser Jamil
School of Biotechnology- MGNIRSA
Street no-17, GaganMahal Road, Domalguda
Hyderabad- 500029, A.P. India
+91- 40-66631500
E-mail : [email protected]

Received Date: November 06, 2009; Accepted Date: December 28, 2009; Published Date: December 28, 2009

Citation: Jamil K, Kumar K, Fatima SH, Rabbani S, Kumar R, et al. (2009) Clinical Studies on Hormonal Status in Breast Cancer and its Impact on Quality of Life (QOL). J Cancer Sci Ther 1: 083-089. doi: 10.4172/1948-5956.1000013

Copyright: © 2009 Jamil K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Breast cancer is a steroid hormone–dependent tumor. Stratification of patients according to hormone (ER/ PR) receptor status and nodal metastasis is of great therapeutic importance. In this investigation, we could enroll 79 pre and post-menopausal breast cancer patients voluntarily. We classified these cases into four categories of the combinations of ER/PR positive, negative and mixed statuses. Their hormone receptor status as determined by immunohistochemistry correlated with therapy regimens like chemotherapy, hormone therapy and QOL responses. We found that in ER+/PR- and ER-/PR- tumors were more frequent in postmenopausal women than ER+/PR+ tumors. The ER+/PR- tumors were larger than ER+/PR+ tumors. In addition, 21.51% of ER+/PR- and 17.72% of ER-/PR- patients had four or more axillary nodes involved with tumors compared to patients with ER+/PR+ tumors (7.59%). Postmenopausal women with ER+/PR- and ER-/PR- who received adjuvant hormonal therapy or combination of chemo drugs like Cyclophosphamide, Adriamycin, 5-FU (FAC) and Cyclophosphamide, Alurubicin, 5-FU (CAF) showed good response than premenopausal women. Forty patients receiving tamoxifen (hormone therapy) along with other chemo- drugs also showed good response. Tamoxifen induced substantial tumor regression and increased disease free survival. It is concluded that hormone receptor status is important in deciding the choice of treatment for all subgroups and influenced the QOL. Another significant observation was that the frequency of ER+/PR- and ER-/PR- tumors was higher in this study group compared to ER+/PR+ tumors. This is the first report from south Indian population indicating the importance of hormonal status in deciding therapeutic regimens in breast cancer patients affecting their QOL.


Share This Page